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Abstract 
Bladder cancer (BC) is the ninth most malignant tumor worldwide. Some BC patients will 
develop muscle-invasive BC (MIBC), which has a 5-year survival rate of approximately 60% 
due to metastasis. As such, there is an urgent need for novel therapeutic and diagnostic targets 
for MIBC. Analysis of novel antitumor-microRNA (miRNA)-mediated cancer networks is an 
effective strategy for exploring therapeutic targets and prognostic markers in cancers. Our 
previous miRNA analysis revealed that miR-140-5p acts as an antitumor miRNA in BC cells. 
Here, we investigated miR-140-5p regulation of BC molecular pathogenesis. Procollagen-lysine, 
2-oxoglutarate 5-dioxygenase 1 (PLOD1) was found to be directly regulated by miR-140-5p, 
and aberrant expression of PLOD1 was observed in BC clinical specimens. High PLOD1 
expression was significantly associated with a poor prognosis (disease-free survival: P = 
0.0204; overall survival: P = 0.000174). Multivariate analysis showed PLOD1 expression to be 
an independent prognostic factor in BC patients (hazard ratio = 1.51, P = 0.0099). Furthermore, 
downregulation of PLOD1 by siRNAs and a specific inhibitor significantly decreased BC cell 
aggressiveness. Aberrant expression of PLOD1 was closely associated with BC pathogenesis. In 
summary, the present study showed that PLOD1 may be a potential prognostic marker and 
therapeutic target for BC. 
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Introduction 
Bladder cancer (BC) is the ninth most malignant tumor worldwide, and approximately 
430,000 cases were newly diagnosed in 2012 (Antoni et al., 2017). BC is clinically divided into 
two groups: muscle-invasive BC (MIBC) and non-muscle-invasive BC (NMIBC) (Lemke and 
Shah, 2018). Patients with the latter have a favorable prognosis (5-year survival rate:  
approximately 90%) after surgical resection. However, approximately 50% of cases develop 
intravesical recurrence after surgical resection, and approximately 15–40% of recurrent BC 
cases are invasive and exhibit distant metastasis (Lemke and Shah, 2018). Although radical 
cystectomy and cisplatin-based combination chemotherapy are the standard treatments for 
MIBC, the 5-year survival rate of patients with MIBC is approximately 60% (Chou et al., 2016; 
Lemke and Shah, 2018). In addition, the survival of patients with distant metastasis is only 15 
months due to no effective treatment options (Abufaraj et al., 2018). Therefore, discovery of 
novel therapeutic and diagnostic targets is urgently needed. 
A vast number of studies have shown that a large number of noncoding RNAs encoded by 
the human genome are functional and play critical roles in various cellular processes, e.g., cell 
growth, migration, invasion and apoptosis (Bartel, 2004). microRNAs (miRNAs), a class of 
noncoding RNAs, are endogenous single-stranded RNA molecules comprising 19–22 
nucleotides that function as fine-tuners of RNA expression (Bartel, 2009; Goto et al., 2015b; 
Koshizuka et al., 2017a; Kurozumi et al., 2017). A single miRNA regulates a vast number of 
RNA transcripts, and a bioinformatics study showed that approximately 60% of protein-coding 
genes are controlled by miRNAs (Bartel, 2009). Aberrantly expressed miRNAs are closely 
associated with cancer pathogenesis via disruption of RNA networks within cancer cells 
(Beermann et al., 2016). 
Using the knowledge that a single miRNA controls numerous genes, we sequentially 
identified novel cancer pathways regulated by antitumor miRNAs in several cancers (Goto et al., 
2015a; Goto et al., 2017; Miyamoto et al., 2016). Identification of dysregulated miRNAs in 
cancer cells is the first step, and the latest RNA-sequencing technology is suitable for producing 
miRNA signatures. Interestingly, analyses of our RNA-sequencing-based signatures revealed 
that the passenger strand of some miRNAs is up- or down-regulated in cancer tissues(Koshizuka 
et al., 2017b) (Goto et al., 2017; Koshizuka et al., 2017c). During miRNA biogenesis, the 
passenger strand of the miRNA duplex is degraded and does not play a role in gene regulation in 
cells (Mah et al., 2010). Our recent studies revealed that the passenger strand of certain miRNAs 
(e.g., miR-99a-3p, miR-144-5p, miR-145-3p, miR-455-5p and miR-223-5p) acts as an antitumor 
miRNA by targeting several oncogenic genes closely involved in cancer pathogenesis (Arai et 
al., 2018a; Arai et al., 2018b; Goto et al., 2017; Matsushita et al., 2015; Sugawara et al., 2018; 
Yamada et al., 2018a, b).  
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Based on the miRNA signature of BC, we focused on miR-140-5p (the passenger strand 
of the miR-140-duplex) to investigate the function of miR-140-5p and identify its target 
oncogenes as therapeutic and diagnostic targets for BC. Our data showed that 
procollagen-lysine, 2-oxoglutarate 5-dioxygenase 1 (PLOD1) is directly regulated by 
miR-140-5p in BC cells. Aberrant expression of PLOD1 was closely associated with BC 
pathogenesis. Notably, inhibition of PLOD1 by transfection of siRNA or a PLOD1 inhibitor 
significantly attenuated the malignant phenotype of BC cells.  
 
 
Materials and Methods 
Clinical specimen collection and cell culture 
We obtained 15 BC tissues and normal adjacent tissues from patients undergoing total 
cystectomy at Chiba University Hospital between 2014 and 2015 (Table S1). All patients 
provided informed written consent forms, and the study protocol was approved by the 
Institutional Review Board of Chiba University (number: 484). The study methodologies 
conformed to the standards set by the Declaration of Helsinki. We used the human BC cell lines 
T24 and BOY. These cell lines were cultured in RPMI 1640 medium supplemented with 10% 
fetal bovine serum (HyClone, Logan, UT, USA) as described previously (Yamada et al., 2018e). 
 
Transfection of mature miRNAs, siRNAs and plasmid vectors. 
We used the following agents in this study: the precursor sequences of hsa-miR-140-5p 
and hsa-miR-140-3p (assay IDs: PM10205 and PM12503, respectively; Applied Biosystems, 
Foster City, CA, USA), negative control miRNA (miR-control) (assay ID: AM 17111; Applied 
Biosystems) and PLOD1-specific siRNA (si-PLOD1) (Stealth Select RNAi siRNA, P/N: 
HSS108122 and HSS108123; Invitrogen, Carlsbad, CA, USA). A plasmid vector containing 
PLOD1 was provided by ORIGENE (cat. no. SC119956; Rockville, MD, USA). Transfection of 
the agents into cells was performed using previously described procedures(Yamada et al., 
2018d) (Yamada et al., 2018c). miRNAs and siRNAs were incubated with 10 nM Lipofectamine 
RNAi Max transfection reagent (Invitrogen) diluted in Opti-MEM (Invitrogen). Plasmid vectors 
were incubated with Lipofectamine 3000 reagent (Invitrogen) in Opti-MEM for forward 
transfection.  
 
PLOD1 inhibitor studies 
We used 2,2’-dipyridyl (07-5990; Sigma-Aldrich), previously reported to be a 
small-molecule PLOD1 inhibitor, to inhibit PLOD1 in in vitro assays (Jover et al., 2018). 
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Quantitative reverse-transcription polymerase chain reaction (qRT-PCR) 
TaqMan probes and primers specific to PLOD1 (P/N: Hs00609363_m1; Applied 
Biosystems), which are assay-on-demand gene expression products, were used to analyze 
PLOD1 expression. miR-140-5p (P/N:001187; Applied Biosystems) and miR-140-3p 
(P/N:002234; Applied Biosystems) expression was analyzed by qRT-PCR. mRNA and miRNA 
expression levels were normalized to those of GUSB (P/N: Hs99999908_m1; Applied 
Biosystems) and RNU48 (assay ID: 001006; Applied Biosystems). PCR quantification was 
performed as described previously (Yamada et al., 2018e). 
 
Cell proliferation、migration and invasion assays 
Cell proliferation was evaluated by the XTT assay using the Cell Proliferation Kit II 
(Sigma-Aldrich, St. Louis, MO, USA). Cell migration was assessed by wound healing assays, 
and invasion was determined using modified Boyden chambers containing Matrigel-coated 
Transwell membrane filter inserts. 
 
Cell cycle assay 
BC cells were transiently transfected with either the transfection reagent only as the 
control or the 2,2’-dipyridyl, PLOD1 inhibitor in six-well tissue culture plates. Cells were 
harvested by trypsinization 72 h after transfection. For cell-cycle analysis, cells were stained 
with propidium iodide using the Cycletest PLUS DNA Reagent Kit (BD Biosciences, Bedford, 
MA, USA) according to the manufacturer’s instructions and examined using the CyAn ADP 
analyzer (Beckman Coulter, Brea, CA, USA). The percentages of cells in the G0/G1, S and 
G2/M phases were calculated and compared. Experiments were performed in triplicate 
(Matsushita et al., 2015). 
 
Apoptosis assays  
Apoptotic cells were detected using the FITC Annexin V Apoptosis Detection Kit (BD 
Biosciences) according to the manufacturer’s instructions and the BD FACS Celesta Flow 
Cytometer (BD Biosciences). Cells were identified as viable, dead, or early or late apoptotic 
cells, and the percentages of apoptotic cells under each experimental condition were compared. 
Anti-poly (ADP-ribose) polymerase (PARP) (#9542; Cell Signaling Technology, Danvers, MA, 
USA) was evaluated as a marker of apoptosis in this study (Idichi et al., 2018).  
 
Western blotting 
Western blotting was performed using a polyclonal anti-PLOD1 antibody (1:1000 
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dilution; SAB1301577; Sigma-Aldrich) and an anti-glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) antibody (1:10 000 dilution; ab8245; Abcam, Cambridge, UK) as a control 
(Fukumoto et al., 2015; Fukumoto et al., 2014).  
 
miR-140-5p and miR-140-3p localization within the RNA-induced silencing complex (RISC) 
using Ago2 immunoprecipitation 
T24 cells were transfected with 10 nM miRNA by reverse transfection. After 72 h, 
immunoprecipitation of the RISC was performed using the Ago2 miRNA isolation kit (Wako, 
Osaka, Japan). The expression levels of miR-140-5p and miR-140-3p in the immunoprecipitates 
were analyzed by qRT-PCR. miRNA expression levels were normalized to that of miR-26a 
(P/N: 000405; Applied Biosystems), which was not affected by miR-140-5p or miR-140-3p 
transfection. 
 
Identification of candidate target genes regulated by miR-140 
To identify candidate target genes regulated by miR-140-5p and miR-140-3p, we used a 
combination of in silico and genome-wide gene expression analyses. Genes potentially 
regulated by miRNAs in a sequence-dependent manner are listed in the TargetScan database 
(release 7.2) (http://www.targetscan.org/vert_70/). Genes upregulated in BC were identified 
from a publicly available dataset in the Gene Expression Omnibus (GEO; accession number: 
GSE31684), and we narrowed down the list of candidate genes. Gene expression was also 
analyzed by our own oligonucleotide microarray analyses (Human GE 60K; Agilent 
Technologies), the data of which were deposited into the GEO (on June 14, 2018; 
http://www.ncbi.nlm.nih.gov/geo/) under accession number GSE115800. 
 
Dual-luciferase reporter assay  
The wild-type sequence of the PLOD1 3’-untranslated region (UTR) was inserted 
between the SgfI and PmeI restriction sites of the 3’-UTR of the hRluc gene within the 
psiCHECK-2 vector (C8021; Promega, Madison, WI, USA). We also generated PLOD1 3’-UTR 
sequences containing deletions in the miR-140-5p target sites (positions 43–49 and 725-731) for 
insertion into the psiCHECK-2 vector as described above. The psiCHECK-2 vector was used as 
a cloning vector for the synthesized DNA sequences.  
 
Immunohistochemistry 
Immunohistochemistry procedures were performed according to a previously described 
method. Clinical tissue sections were incubated overnight at 4°C with an anti-PLOD1 antibody 
diluted 1:10 (SAB1301577; Sigma-Aldrich).  
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Analysis of genes downstream of PLOD1  
To investigate PLOD1-regulated pathways in BC cells, we assessed gene expression 
changes in T24 and BOY cells transfected with the PLOD1 inhibitor. Microarray analysis was 
performed to obtain expression profiles in these cells, and the microarray data were deposited 
into the GEO (on December 4, 2018; accession number: GSE123318). 
 
Analysis of the clinical significance of PLOD1 expression 
We investigated the clinical importance of miRNAs and genes in BC patients using RNA 
sequencing data available in The Cancer Genome Atlas (TCGA; 
https://tcga-data.nci.nih.gov/tcga/). The gene expression and clinical data were obtained from 
cBioportal (http://www. cbioportal.org/), and provisional data were downloaded on October 5, 
2018 (Cerami et al., 2012; Gao et al., 2013; J, 2016).  
 
Statistical analysis  
Statistical comparisons involving two or three variables were performed using the 
Bonferroni-adjusted Mann–Whitney U test. Spearman’s rank tests were used to analyze the 
correlations among gene expression levels. These analyses were conducted using Expert 
StatView software (version 5.0, SAS Institute Inc., Cary, NC, USA). Multivariate analysis of 
prognostic factors for patient survival was conducted using JMP Pro 13. 
 
 
Results 
Expression of miR-140-5p and miR-140-3p in BC tissues 
hsa-miR-140 is located on chromosome 16q22.1 in humans. The mature sequences of 
miR-140-5p and miR-140-3p are 5’-CAGUGGUUUUACCCUAUGGUAG-3’ and 
5’-UACCACAGGGUAGAACCACGG-3’, respectively. The expression levels of miR-140-5p 
and miR-140-3p were significantly downregulated in BC tissues compared with adjacent normal 
tissues (P = 0.0013 and P = 0.0004, respectively; Figure 1A and B). Moreover, Spearman’s rank 
test revealed a strong positive correlation between miR-140-5p and miR-140-3p expression 
levels (R = 0.637, P = 0.0006; Figure 1C). 
 
Effect of miR-140-5p and miR-140-3p on the proliferation, migration and invasion of BC 
cells 
Restoration of miR-140-5p and miR-140-3p significantly suppressed BC cell proliferation, 
migration and invasion abilities (Figure 1D–F). 
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Effect of miR-140-5p and miR-140-3p on apoptosis and cell-cycle assays in BOY cells 
The percentage of apoptotic cells was significantly increased in miR-140-5p and 
miR-140-3p-transfected cells compared with the control cells (Figure S1A, B). Moreover, 
transfection of miR-140-5p and miR-140-3p upregulated the level of cleaved PARP (Figure 
S1C). In a cell-cycle analysis, the proportion of cells in the G0/G1 phase was significantly 
higher transfected with miR-140-5p compared with the control cells (Figure S1D). 
 
miR-140-5p and miR-140-3p localization within the RISC 
We performed immunoprecipitation assays using antibodies targeting Ago2, which plays a 
pivotal role in the uptake of miRNAs into the RISC. After transfection of T24 cells with 
miR-140-5p and immunoprecipitation using anti-Ago2 antibodies, miR-140-5p levels in the 
immunoprecipitates were significantly higher than those in the immunoprecipitates from mock- 
or miR-control-transfected cells as well as miR-140-3p-transfected cells (P < 0.0001; Figure 
S2A). Similarly, after miR-140-3p transfection, substantial levels of miR-140-3p were detected 
in Ago2 immunoprecipitates compared with the controls (P < 0.0001; Figure S2B). 
 
Candidate target genes of miR-140-5p and miR-140-3p in BC cells 
We identified genes containing putative target sites for miR-140-5p and 
miR-140-3p within their 3’-UTR sequence that also showed upregulated expression levels (log2 
> 0.5) in BC tissues and downregulated expression levels (log2 < −0.5) in T24 cells transfected 
with miR-140-5p or miR-140-3p (Figure 2A). Using this strategy, we identified 31 and 33 genes 
as candidate target genes of miR-140-5p and miR-140-3p, respectively (Table 1A and 1B). 
Among these genes, we focused on PLOD1, which was found to be a target of the miR-140-5p 
passenger strand.  
 
Clinical significance and expression of PLOD1 
Clinical data from BC patients were obtained from TCGA database, and information on 
survival revealed that patients with high PLOD1 expression had a significantly poorer prognosis 
compared with patients with low expression (disease-free survival: P = 0.0204; overall survival: 
P = 0.000174; Figure 2B). High PLOD1 expression was also related to a highly malignant 
tumor morphology, advanced stage and metastasis (Figure S3A). According to multivariate Cox 
proportional hazards regression, high expression of PLOD1 was an independent predictive 
factor for overall survival in BC patients (hazard ratio: 1.51, 95% confidence interval: 1.1–2.07, 
P = 0.0099) (Figure 2B). PLOD1 mRNA expression levels were significantly upregulated in BC 
tissues compared with normal adjacent tissues (P = 0.0464) (Figure 2C). Immunostaining of 
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PLOD1 in BC clinical specimens indicated high expression of PLOD1 in cancer lesions 
compared with adjacent noncancerous tissues at the same staining intensity (Figure 2C). 
In addition, expression levels of PLOD2 and PLOD3 were detected in BC clinical 
specimens (Figures S4A and S4B). Also, immunohistochemical staining showed that 
overexpressed PLOD2 and PLOD3 were detected in cancer lesions ((Figures S4G and S4H). 
Interestingly, high expression of PLOD2 was significantly associated with poor prognosis of the 
patients with BC ((Figure S3B). Among PLOD family, expression of PLOD1 was the highest in 
BC tissues (Figure S4C). Clinicopathological analysis was performed between PLODs 
expression and BC (NMIBC or MIBC) clinical specimens. However, no significant association 
was found in this study (Figure S4 D-F). 
 
PLOD1 was directly regulated by miR-140-5p 
PLOD1 mRNA and protein levels were significantly decreased in T24 and BOY cells 
following transfection with miR-140-5p compared with mock-transfected cells or those 
transfected with miR-control (Figure 2D and E). The TargetScan database indicated the 
presence of two miR-140-5p binding sites (positions 43–49 and 725–731) within the PLOD1 
3’-UTR. We performed luciferase reporter assays using a vector containing these sequences to 
assess whether miR-140-5p directly regulates PLOD1 expression in a sequence-dependent 
manner. Cotransfection of miR-140-5p with vectors harboring the PLOD1 3’-UTR deletion 
constructs significantly decreased luciferase activity compared with the activity levels in 
mock-transfected and miR-control-transfected cells (Figure 2F). 
 
Knockdown and rescue studies of PLOD1 
We confirmed that both PLOD1 mRNA and protein expression levels were suppressed by 
siRNA-mediated PLOD1 knockdown in BC cells (Figure 3A and B). Transfection of si-PLOD1 
suppressed cell proliferation, migration and invasion activities (Figure 3C–E). The percentage 
of apoptotic cells was significantly increased in si-PLOD1-transfected cells compared with the 
control cells (Figure S5A, B). Moreover, transfection of si-PLOD1 upregulated the level of 
cleaved PARP (Figure S5C). In a cell-cycle analysis, the proportion of cells in the G0/G1 phase 
was significantly higher transfected with si-PLOD1_2 compared with the control cells, although 
G2/M phase was significantly elevated in si-PLOD1_1 transfection (Figure S5D). 
In addition, we performed a PLOD1 rescue study in T24 cells to validate whether 
oncogenic pathways regulated by PLOD1/miR-140-5p are crucial for BC development. 
PLOD1 and miR-140-5p transfection restored PLOD1 protein expression (Figure 3F). 
Functional assays demonstrated that BC cell migration and invasion were significantly 
recovered by PLOD1 and miR-140-5p transfection compared with miR-140-5p alone (Figure 
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3G–I).  
 
Functional analysis of a PLOD1 inhibitor 
After transfection of the PLOD1 inhibitor 2,2’-dipyridyl into BC cells, cell 
proliferation was suppressed in a dose-dependent manner (Figure 4A). The IC50 of 
2,2’-dipyridyl was 82.8 µM in BOY cells and 37.1 µM in T24 cells. Cell migration and invasion 
were also decreased in a dose-dependent manner in cells transfected with the inhibitor (Figure 
S6). In addition, the percentage of apoptotic cells was increased in PLOD1-inhibitor-transfected 
cells compared with the control cells (Figure 4B). Moreover, transfection of PLOD1 inhibitor 
upregulated the level of cleaved PARP (Figure 4B). In a cell-cycle analysis, the proportion of 
cells in the G0/G1 phase was significantly higher in BC cells transfected with the PLOD1 
inhibitor compared with the control cells (Figure 4C). In addition, we confirmed that the 
inhibitor suppressed the mRNA and protein levels of PLOD1 in a dose-dependent manner 
(Figure S7).  Apoptosis and cell-cycle experiments gave similar results in BOY cells (Figure 
S8). 
 
Genes affected by the PLOD1 inhibitor 
PLOD1 acts as lysyl hydroxylases catalyze hydroxylation of collagen lysines, and it 
works under the following conditions, extracellular matrix maturation and remodeling. In order 
to explore the functional significance of PLOD1 on tumor progression, we examined the 
PLOD1 mediated downstream genes and pathways. As shown in the Venn diagram in Figure S9, 
1,518 genes were considerably downregulated after transfection of the PLOD1 inhibitor in BOY 
and T24 cells. In a KEGG analysis of these genes, we identified 39 pathways enriched among 
the PLOD1-affected genes, including pathways related to cell cycle and apoptosis (Table 2).  
 
 
Discussion 
RNA-sequencing is a suitable technology for creating miRNA expression signatures in 
cancer cells. Analyses of our miRNA signatures in cancers revealed that the passenger strand of 
some miRNA duplexes is functional in cancer cells by targeting cancer-related genes (Arai et al., 
2018b; Goto et al., 2017; Matsushita et al., 2015; Sugawara et al., 2018; Yamada et al., 2018a, 
b). This makes it possible to identify novel cancer pathways based on aberrantly expressed 
passenger- strand miRNAs.  
In this study, we focused on both strands of pre-miR-140 (miR-140-5p and miR-140-3p) and 
revealed their antitumor functions in BC cells. Previous reports showed that miR-140-3p is 
downregulated in squamous cell lung cancer and functions as a tumor suppressor by targeting 
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bromodomain containing 9 in vitro and in vivo (Huang et al., 2019). As with miR-140-3p, a 
tumor-suppressive function of miR-140-5p has been reported in several cancers. miR-140-5p 
exerted a tumor suppressive function and enhanced the effect of existing therapeutic drugs in 
non-small cell lung cancer (Flamini et al., 2017). Another report showed that miR-140-5p 
suppressed cell aggressiveness and suggested that miR-140-5p is a prognostic marker in gastric 
cancer (Fang et al., 2017). Downregulation of miRNAs was reported to be caused by epigenetic 
factors such as DNA methylation or histone deacetylation. Previous study showed that 
suppression of miR-140 expression was influenced by the hypermethylation of the promoter 
region in breast cancer (Wolfson et al., 2014). Elucidation of the detailed molecular mechanism 
of downregulation of miR-140-5p and miR-140-3p is also essential in BC cells. These studies 
indicate that both strands of pre-miR-140 act as critical miRNAs that prevent malignant 
transformation in cells. To our knowledge, this is the first study to identify a functional role of 
the miR-140 duplex and its oncogene targets in BC. 
Our next focus was to investigate the molecular networks regulated by these miRNAs in 
BC cells. A total of 31 genes regulated by miR-140-5p and 33 genes regulated by miR-140-3p 
were identified as putative oncogenic targets in BC cells. Among these targets, the expression 
levels of eight genes (CERCAM, PLOD1, FADS1, PAFAH1B2, PAX6, ADAM17, CCDC103 and 
PLXNA4) were closely associated with BC pathogenesis. These genes are promising as 
therapeutic targets and prognostic markers, and further analysis is necessary to elucidate the 
molecular pathogenesis of BC. We focused on PLOD1 to investigate its oncogenic functions 
and clinical significance in BC. PLOD genes encode lysyl hydroxylases, which are crucial for 
collagen biosynthesis, cross-linking and deposition (Qi and Xu, 2018). Collagen is a major 
component of the extracellular matrix (ECM), and collagen cross-linking is related to the 
stiffness of the ECM, which enhances cancer cell migration, invasion and focal adhesion (Du et 
al., 2017; Peinado et al., 2008). The PLOD family consists of PLOD1, PLOD2 and PLOD3. A 
number of studies have demonstrated that overexpression of PLOD2 and PLOD3 promotes 
cancer progression and metastasis. Our previous studies showed that aberrant expression of 
PLOD2 was detected in BC and renal cell carcinoma tissues and its overexpression enhanced 
cancer cell malignant transformation (Kurozumi et al., 2016; Miyamoto et al., 2016). We 
hypothesized that members of the PLOD-family member are deeply involved in the molecular 
pathogenesis of BC. On the other hand, there are not many reports on the role of PLOD1 in 
cancer (Qi and Xu, 2018). Previous studies showed that aberrant expression of PLOD1 was 
significantly associated with shorter survival in patients with gastric or colorectal cancer (Wang 
et al., 2018). Overexpression of PLOD1 was also detected in esophageal squamous cell 
carcinoma and breast cancer (Gilkes et al., 2013; Li et al., 2017). Mutations in PLOD1 are the 
cause of PLOD1-related kyphoscoliotic Ehlers–Danlos syndrome, an autosomal recessive 
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generalized connective tissue disorder (Giunta et al., 2005). 
The data from a large number of cohort analyses in TCGA database show that high 
expression of PLOD1 is significantly associated with a poor prognosis (overall survival: P = 
0.000174), more strongly than are PLOD2 and PLOD3 (OS: P = 0.0097 and P = 0.315, 
respectively) (Figure S3B and C). Furthermore, multivariate analysis showed that PLOD1 
expression was an independent prognostic factor in patients with BC (hazard ratio = 1.51, P = 
0.0099). Moreover, high expression of PLOD1 was significantly associated with tumor stage 
and presence of metastasis. Aberrant expression of PLOD1 has been shown to be closely related 
to the malignant phenotype of BC. Development of a new diagnostic strategy for BC using 
PLOD1 expression as a marker is desired. 
Aberrant expression of PLOD1 was detected in BC clinical specimens, and inhibition of 
PLOD1 by siRNA-mediated knockdown or treatment with a PLOD1 inhibitor significantly 
reduced the malignant phenotype of BC cells (e.g., decreases in proliferation, migration and 
invasion and an increase in apoptosis). We used 2,2’-dipyridyl, an iron chelator, as an inhibitor 
of PLOD1 in this study (Bernardes et al., 2018; Jover et al., 2018). Collagen lysyl hydroxylases 
reportedly depend on Fe2+ binding for stabilization, and 2,2’-dipyridyl prevents prolyl and lysyl 
hydroxylation (Barsh and Byers, 1981; Guo et al., 2018). A previous report showed that 
inhibition of PLOD1 and lysyl oxidase suppressed arterial smooth muscle cell calcification via 
ECM remodeling (Jover et al., 2018). Another study was conducted to investigate the effect of 
2,2’-dipyridyl in combination with doxorubicin in breast cancer cells (Bernardes et al., 2018). In 
this study, we showed that PLOD1 expression and cell proliferation were suppressed after 
transfection of a PLOD1 inhibitor in a dose-dependent manner. Moreover, the PLOD1 inhibitor 
induced apoptosis and cell-cycle arrest at the G1-to-S phase transition. 
The molecular mechanism of the antitumor effect of the PLOD1 inhibitor in BC cells was 
evaluated by global gene expression analysis. As a result, genes associated with cell cycle, 
ECM–receptor interactions and apoptosis were differentially expressed in cells transfected with 
the PLOD1 inhibitor, supporting our current data. We focused on several genes (e.g., CCNB1, 
CCNB2 and SKP2) involved in “cell-cycle pathway”. Expression of CCNB2 (cyclin B2) was 
upregulated in BC tissues and suppression of its expression significantly inhibited invasive and 
metastatic abilities (Lei et al., 2016). Our recent study showed that CCNB1 (cyclin B1) was 
regulated by antitumor miR-223-5p in BC cells and its high expression was closely associated 
with poor prognosis of the patients with BC by TCGA database analysis (Sugawara et al., 2018). 
Moreover, overexpression of SKP2 (S-phase kinase-associated protein 2) as significantly related 
to advanced tumor stage and grade of the patients with BC (Kawakami et al., 2007). 
Moreover, we performed rescue experiments by overexpressing PLOD1 and miR-140-5p. 
The results revealed that PLOD1 can counteract the antitumor effects, in terms of cell migration 
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and invasion, of miR-140-5p in BC cells, indicating that the PLOD1/miR-140-5p axis plays an 
important role in BC development. 
 
 
Conclusion 
Both strands of the miR-140 duplex (miR-140-5p and miR-140-3p) suppressed BC cell 
malignant transformation. Genes controlled by the miR-140-5p was found to be related to BC 
pathogenesis. PLOD1 expression was directly regulated by the miR-140-5p in BC cells. 
Aberrant expression of PLOD1 was closely contributed to BC development. Furthermore, 
inhibition of PLOD1 expression significantly attenuated to BC cell aggressive phenotypes. 
PLOD1 might be a novel biomarker and therapeutic target in BC. Further investigation is 
required for clinical application. 
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Figure legends 
Figure 1. miR-140 expression and antitumor functions in BC. 
(A–C) Expression levels of miR-140-5p and miR-140-3p in BC clinical specimens (P = 0.0013 
and P = 0.0004, respectively). RNU48 was used as an internal control. P-values were calculated 
using Bonferroni-adjusted Mann–Whitney U-test. A positive correlation between miR-140-5p 
and miR-140-3p expression levels was detected by Spearman’s rank test (R = 0.637, P = 0.0006). 
(D–F) Cell proliferation, migration and invasion activities. Error bars are represented as mean ± 
SD (n = 5, n = 8, and n = 8, respectively). P-values were calculated using Bonferroni-adjusted 
Mann–Whitney U-test. * P < 0.001, ** P < 0.0001. 
 
Figure 2. Clinical significance, expression and regulation of PLOD1. 
(A) The strategy used to identify miR-140-5p candidate target genes, represented by a Venn 
diagram. (B) Clinical significance of PLOD1. (C) PLOD1 mRNA and protein expression in BC 
tissues. Scale bars of x100 and x400 represent 200 and 50 μm, respectively. P-values were 
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calculated using Bonferroni-adjusted 
Mann–Whitney U-test. (D) PLOD1 mRNA expression levels 48 h after transfection of BC cells 
with 10 nM miR-140-5p. GAPDH was used as the internal control gene. Error bars are 
represented as mean ± SD (n = 3). P-values were calculated using Bonferroni-adjusted Mann–
Whitney U-test. (E) PLOD1 protein expression 72 h after transfection with 10 nM miR-140-5p. 
GAPDH was used as the loading control. (F) Dual luciferase reporter assays using vectors 
encoding the wild-type PLOD1 3′-UTR sequence containing two putative miR-140-5p target 
sites and 3′-UTR sequences with deletions of the target sites (Deletion). Normalized data were 
calculated as the ratio of Renilla/firefly luciferase activities. Error bars are represented as mean 
± SD (n = 3). P-values were calculated using Bonferroni-adjusted Mann–Whitney U-test. * P < 
0.0001, ** P < 0.005. 
 
Figure 3. Knockdown and rescue studies of PLOD1. 
(A, B) PLOD1 mRNA and protein expression 72 h after transfection of si-PLOD1_1 or 
si-PLOD1_2 in BC cell lines. GAPDH was used as the control. Error bars are represented as 
mean ± SD (n = 3). P-values were calculated using Bonferroni-adjusted Mann–Whitney U-test. 
(C) Cell proliferation, (D) migration and (E) invasion activities in BC cells. Error bars are 
represented as mean ± SD (n = 5, n = 8, and n = 8, respectively). P-values were calculated 
using Bonferroni-adjusted Mann–Whitney U-test. (F) PLOD1 protein expression was evaluated 
72 h after reverse transfection of miR-140-5p and 48 h after forward transfection of PLOD1. 
GAPDH was used as the loading control. (G) Cell proliferation assay performed 72 h after 
reverse transfection of miR-140-5p and 48 h after forward transfection of PLOD1. (H) Cell 
migration assay performed 48 h after reverse transfection of miR-140-5p and 24 h after forward 
transfection of PLOD1. (I) Cell invasion assay performed 48 h after reverse transfection of 
miR-140-5p and 24 h after forward transfection of PLOD1. Error bars are represented as mean ± 
SD (n = 5, n = 8, and n = 8, respectively). P-values were calculated using Bonferroni-adjusted 
Mann–Whitney U-test. * P < 0.0001. 
 
Figure 4. Functional analysis of a PLOD1 inhibitor. 
(A) Cell proliferation assay of BC cells transfected with an inhibitor of PLOD1 and the IC50 
values of the PLOD1 inhibitor. IC50 values were calculated using JMP software. Error bars are 
represented as mean ± SD (n = 5). P-values were calculated using Bonferroni-adjusted Mann–
Whitney U-test. (B) Effect of the PLOD1 inhibitor on apoptosis, as assessed by apoptosis assays 
and western blot analysis of cleaved PARP, as a marker of apoptosis. GAPDH was used as the 
loading control. Error bars are represented as mean ± SD (n = 3). P-values were calculated using 
Bonferroni-adjusted Mann–Whitney U-test. (C) Effect of the PLOD1 inhibitor on the cell-cycle. 
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The bar charts represent the percentages of inhibitor-transfected cells relative to the control cells 
in the G0/G1, S and G2/M phases, respectively. Error bars are represented as mean ± SD (n = 3). 
P-values were calculated using Bonferroni-adjusted Mann–Whitney U-test. * P < 0.0001. 
 
Table 1 Candidate target genes of miR-140-5p and miR-140-3p in BC. 
 
Table 2. Molecular pathways significantly enriched among the genes affected by PLOD1 
inhibitor treatment in BC cells. 
 
 
Supporting information 
Figure S1. Effect of miR-140-5p and miR-140-3p on apoptosis and cell-cycle assays in BOY 
cells 
(A-C) Effect of miR-140-5p and miR-140-3p on apoptosis, as assessed by apoptosis assays and 
western blot analysis of cleaved PARP, as a marker of apoptosis. GAPDH was used as the 
loading control. Error bars are represented as mean ± SD (n = 3). P-values were calculated using 
Bonferroni-adjusted Mann–Whitney U-test. (D) Effect of miR-140-5p and miR-140-3p on the 
cell-cycle. Flow cytometric analysis of cell-cycle-phase distribution in control cells and cells 
transfected with the miR-140-5p and miR-140-3p. The bar charts represent the percentages of 
inhibitor-transfected cells relative to the control cells in the G0/G1, S and G2/M phases, 
respectively. Error bars are represented as mean ± SD (n = 3). P-values were calculated using 
Bonferroni-adjusted Mann–Whitney U-test. * P < 0.0001. 
 
Figure S2. miR-140-5p and miR-140-3p localization within the RISC. 
Expression of (A) miR-140-5p and (B) miR-140-3p in Ago2 immunoprecipitates from the 
lysates of cells transfected with miR-140-5p or miR-140-3p. The expression levels relative to 
mock-transfected cells are shown. Error bars are represented as mean ± SD (n = 3). P-values 
were calculated using Bonferroni-adjusted Mann–Whitney U-test. * P < 0.0001. 
 
Figure S3. Clinical database analysis of PLOD1, PLOD2 and PLOD3 expression in BC 
patients. 
(A) Relationships of PLOD1 expression with tumor morphology, stage and metastatic status. 
(B) Relationships of PLOD2 expression with tumor morphology, stage, metastatic status and 
prognosis. (C) Relationships of PLOD3 expression with tumor morphology, stage, metastatic 
status and prognosis. P-values were calculated using Bonferroni-adjusted Mann–Whitney 
U-test. 
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Figure S4. Expression analysis of PLOD1, PLOD2 and PLOD3 in BC tissues. 
(A) PLOD2 mRNA expression in BC tissues. (B) PLOD3 mRNA expression in BC tissues. (C) 
Comparison of POD1, PLOD2 and PLOD3 expression in BC tissues. (D) Comparison of 
expression of PLOD2 in NMIBC and MIBC. (E) Comparison of expression of PLOD3 in 
NMIBC and MIBC. (F) Comparison of expression of PLOD1 in NMIBC and MIBC. Error bars 
are represented as mean ± SD. P-values were calculated using Bonferroni-adjusted Mann–
Whitney U-test. (G) PLOD2 protein expression in BC tissues. (H) PLOD3 protein expression in 
BC tissues. Scale bars of x100 and x400 represent 200 and 50 μm, respectively. 
 
Figure S5. Effect of si-PLOD1 on apoptosis and cell-cycle assays in BOY cells 
(A-C) Effect of si-PLOD1 on apoptosis, as assessed by apoptosis assays and western blot 
analysis of cleaved PARP, as a marker of apoptosis. GAPDH was used as the loading control. 
(D) Effect of si-PLOD1 on the cell-cycle. Flow cytometric analysis of cell-cycle-phase 
distribution in control cells and cells transfected with the si-PLOD1. The bar charts represent 
the percentages of inhibitor-transfected cells relative to the control cells in the G0/G1, S and 
G2/M phases, respectively. Error bars are represented as mean ± SD (n = 3). P-values were 
calculated using Bonferroni-adjusted Mann–Whitney U-test. * P < 0.0001. 
 
Figure S6. Effect of a PLOD1 inhibitor on the migration and invasion of BC cells. 
(A) Cell migration and (B) invasion assays after transfection of the PLOD1 inhibitor at 
concentrations of 100 or 300 µM. Error bars are represented as mean ± SD (n = 8 and n = 8, 
respectively). P-values were calculated using Bonferroni-adjusted Mann–Whitney U-test. * P < 
0.0001. Scale bars represent 200 μm.  
 
Figure S7. Effect of a PLOD1 inhibitor on PLOD1 expression. 
(A) mRNA and (B) protein levels of PLOD1 after PLOD1 inhibitor transfection. GAPDH was 
used as the control. 
 
Figure S8. Effect of a PLOD1 inhibitor on apoptosis and cell-cycle assays in BC cells. 
(A) Effect of the PLOD1 inhibitor on apoptosis. (B) Effect of the PLOD1 inhibitor on the 
cell-cycle. Flow cytometric analysis of cell-cycle-phase distribution in control cells and cells 
transfected with the PLOD1 inhibitor. 
 
Figure S9. Downstream pathways affected by treatment with a PLOD1 inhibitor in BC 
cells. 
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